Procept BioRobotics(NASDAQ) PRCT

PROCEPT BioRobotics Corporation NASDAQ:PRCT makes robots that treat prostate disease. These machines use high-pressure water to remove tissue without heat. This method helps patients recover from urinary problems faster.

Precision Surgery With Water

• Robotic Systems: Advanced platforms like AquaBeam and HYDROS that guide surgeons through urological procedures.
• Aquablation Therapy: A heat-free procedure that removes prostate tissue using real-time imaging and automated waterjets.
• Disposable Handpieces: Single-use tools required for every surgery to ensure safety and precision.
• Support Services: Ongoing maintenance, repair, and extended service contracts for hospitals using the robotic technology.

Scaling Up Global Operations

• Reached a total install base of 1,036 robotic systems worldwide by June 30, 2026.
• Secured positive Medicare coverage in all 50 states to provide better access for patients.
• Introduced the HYDROS Robotic System as a next-generation platform for minimally invasive surgery.
• Amended a $52 million loan agreement in August 2025 to delay principal repayments until 2027.

What Makes the Tech Unique

Procept BioRobotics uses a heat-free waterjet to remove prostate tissue, which avoids the tissue damage caused by traditional heat-based tools. Its automated system provides consistent surgical results regardless of how much experience the surgeon has.

Measuring the Money

• Revenue reached $177.6 million for the six months ended June 30, 2026, up 20% year over year.
• U.S. sales accounted for 88% of total revenue during the six-month period ended June 30, 2026.
• Net loss widened 32% to $58.5 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents totaled $227.9 million as of June 30, 2026.
• Selling, general, and administrative expenses rose 21% to $134.8 million for the six months ended June 30, 2026.

The Big Picture

Procept BioRobotics has evolved from a research firm into a commercial business with a large global footprint. The company is now focused on making its robotic therapy the standard of care for prostate surgery.